arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Janux Therapeutics, Inc.

JANX

$16.50 ▼ -0.97 (-5.55%) at close

7 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Janux Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.0B

Dividend Yield —

Revenue Growth -5.6% ↘

Op. Margin —

ROIC -13.0% ↘

FCF / Share $-1.34 ↘

Trailing P/E —

Price / Book 1.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$10.00M

↓ -5.6% —

Net Income Profit after all expenses

$-113.62M

↓ -64.7% —

FCF / Share Free cash flow per share

$-1.34

↓ -63.5% —

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-5.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-169%)	31.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+287%)	-6.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-177%)	136.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1610%)	—	—	—
EPS Growth YoY (%)	-43.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	3.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	13.2% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-9.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-64.7% Weak ↓ Weak Declining Year-over-year change in net income	-18.4% Weak ↑ Weak Improving Year-over-year change in net income	7.6% Fair ↑ Fair Improving Year-over-year change in net income	-93.0% Weak Weak Year-over-year change in net income	-381.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-63.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	31.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-0.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	-51.8% Weak Weak Year-over-year change in free cash flow	95.8% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	5.1% Fair Fair Compound annual revenue growth over 3 years	42.8% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF Margin (%) (%)	—	-417.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-13.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-7.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-16.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	26.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-15.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-18.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-8.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-29.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-11.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-179%)	-6.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-145%)	-16.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	-19.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-231%)	-8.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-159%)	46.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+209%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-52.33M	$-430.61M	$-19.20M	$-51.43M	$-35.58M	$-7.81M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.16	$0.20	$0.18	$0.21	$0.15	$0.00	—
Basic EPS, GAAP (USD)	$-1.83	$-1.28	$-1.32	$-1.52	$-1.39	—	—
Free Cash Flow per Share (USD)	$-1.34	$-0.82	$-1.19	$-1.19	$-0.78	$-18.69	—
Book Value per Share (USD)	$15.85	$17.32	$7.44	$7.71	$8.88	$-13.99	—
Tangible Book Value per Share (USD)	$15.85	$17.32	$7.44	$7.71	$8.88	$-13.99	—
Basic Weighted Avg Shares (shares)	61.97M	53.75M	44.02M	41.47M	23.53M	233,726	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$950.89M	$1.02B	$336.21M	$315.93M	$364.22M	$12.88M	—
Total Equity (USD)	$956.82M	$1.02B	$344.35M	$320.74M	$366.33M	$-14.64M	$-7.94M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$10.00M	$10.59M	$8.08M	$8.61M	$3.64M	$0.00	—
Depreciation Expense (USD)	$2.03M	$2.06M	$1.96M	$841.00K	$113.00K	$13.00K	—
Net Income, GAAP (USD)	$-113.62M	$-68.99M	$-58.29M	$-63.06M	$-32.67M	$-6.78M	—
Operating Cash Flow (USD)	$-82.23M	$-43.81M	$-50.58M	$-42.92M	$-16.98M	$-4.37M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Janux Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare JANX with peers